# A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

> **NCT01206764** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 143 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT01206764
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-11
- **Primary completion:** 2017-06-06
- **Final completion:** 2017-07-01
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2019-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206764, "A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01206764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*